AstraZeneca addressed ongoing concerns regarding the side effects of its AstraZeneca-Oxford COVID-19 vaccine, notably rare cases of blood clots and low platelet counts, by reiterating its commitment to patient safety. The statement came as the company faces a class-action lawsuit in the UK over claims linked to Thrombosis Thrombocytopenia Syndrome (TTS) that the vaccine allegedly causes in very rare instances.
Marketed in India as Covishield and produced by the Serum Institute of India, the vaccine has been widely administered across the country. This acknowledgment by AstraZeneca isn’t the first, as the company has previously conceded the possibility of such side effects during the course of the pandemic.
In a recent statement, AstraZeneca expressed its sympathy for those who have suffered health issues or lost loved ones, emphasizing that “Patient safety is our highest priority.” The pharmaceutical giant assured that all its products, including vaccines, meet the stringent safety standards set by global regulatory authorities.
The World Health Organization (WHO) continues to endorse the vaccine as “safe and effective” for all individuals aged 18 and above, stressing that the occurrences of TTS are exceedingly rare. Regulatory bodies worldwide maintain that the benefits of receiving the vaccine far outweigh the potential risks associated with these rare side effects.
The Covishield vaccine utilizes a viral vector platform, employing a modified chimpanzee adenovirus, ChAdOx1, to deliver the COVID-19 spike protein into human cells. This technology is designed to prime the immune system to recognize and combat the virus effectively, without causing actual infection.
For more updates follow our Whatsapp 
and Telegram Channel 
